Identification and development of novel inhibitors of toxoplasma gondii enoyl reductase

Suresh K. Tipparaju, Stephen P. Muench, Ernest J. Mui, Sergey N. Ruzheinikov, Jeffrey Z. Lu, Samuel L. Hutson, Michael J. Kirisits, Sean T. Prigge, Craig W. Roberts, Fiona L. Henriquez, Alan P. Kozikowski, David W. Rice, Rima L. McLeod

Research output: Contribution to journalArticlepeer-review

37 Scopus citations


Toxoplasmosis causes significant morbidity and mortality, and yet available medicines are limited by toxicities and hypersensitivity. Because improved medicines are needed urgently, rational approaches were used to identify novel lead compounds effective against Toxoplasma gondii enoyl reductase (TgENR), a type II fatty acid synthase enzyme essential in parasites but not present in animals. Fifty-three compounds, including three classes that inhibit ENRs, were tested. Six compounds have antiparasite MIC90s ≤ 6 μM without toxicity to host cells, three compounds have IC90s < 45 nM against recombinant TgENR, and two protect mice. To further understand the mode of inhibition, the cocrystal structure of one of the most promising candidate compounds in complex with TgENR has been determined to 2.7 Å. The crystal structure reveals that the aliphatic side chain of compound 19 occupies, as predicted, space made available by replacement of a bulky hydrophobic residue in homologous bacterial ENRs by Ala in TgENR. This provides a paradigm, conceptual foundation, reagents, and lead compounds for future rational development and discovery of improved inhibitors of T. gondii.

Original languageEnglish (US)
Pages (from-to)6287-6300
Number of pages14
JournalJournal of medicinal chemistry
Issue number17
StatePublished - Sep 9 2010

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery


Dive into the research topics of 'Identification and development of novel inhibitors of toxoplasma gondii enoyl reductase'. Together they form a unique fingerprint.

Cite this